Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283204 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2NPSR1ALDH1A1TDP1KDM4E | |
| SCHEMBL283122 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2NPSR1ALDH1A1TDP1KDM4E | |
| SCHEMBL11332004 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2NPSR1ALDH1A1TDP1KDM4E | |
| SCHEMBL3652014 | 0.79 | SIRT6 (0.44) | SMN1; SMN2ALDH1A1TDP1KDM4EKMT2A | |
| SCHEMBL3651785 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2NPSR1ALDH1A1KDM4EKMT2A | |
| SCHEMBL24861312 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1ALDH1A1TDP1KDM4E | |
| SCHEMBL26977894 | 0.78 | NQO2 (0.52) | SMN1; SMN2NPSR1ALDH1A1TDP1KDM4E | |
| SCHEMBL28196232 | 0.77 | TDP1 (0.44) | SMN1; SMN2NPSR1ALDH1A1TDP1KMT2A | |
| SCHEMBL11871085 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1ALDH1A1TDP1KDM4E | |
| SCHEMBL283180 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-12-28 | — | — | US | disclosed |
| EP-3239144-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | Celgene Corporation (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9732064-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2428513-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2420498-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2420497-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150080419-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-8921385-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2066656-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2428513-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420497-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420498-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2066656-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080419-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | SMN1; SMN2 4610/4885NPSR1 771/4885ALDH1A1 1085/4885 |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | SMN1; SMN2 1188/4885NPSR1 1030/4885ALDH1A1 2470/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | SMN1; SMN2 4610/4885NPSR1 771/4885ALDH1A1 1085/4885 |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | SMN1; SMN2 4610/4885NPSR1 771/4885ALDH1A1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.